With Ackman Out, Valeant Confronts Rocky Road to Revival
Even before Valeant Pharmaceuticals International Inc. lost its most vocal cheerleader last week, with the exit of hedge-fund mogul Bill Ackman, Wall Street analysts were virtually unanimous: the company's old business model is broken. Growth, if there is any, will come slowly.
from Biotech News
0 Comments